A committee of Japan's health ministry has approved US biotechnology company Novavax Inc's (Nasdaq:NVAX) COVID-19 vaccine, Reuters news agency reported on Monday.
If granted full approval, this will be Japan's fourth COVID-19 vaccine.
The Japanese government has reportedly agreed to purchase 150 million doses of Novavax's recombinant protein type vaccine, which will be manufactured in Japan by Takeda Pharmaceutical Co (Tokyo:4502).
So far, most of Japan's COVID-19 vaccinations have been carried out with the mRNA vaccines made by US pharmaceutical companies Pfizer Inc (NYSE:PFE) and Moderna Inc (Nasdaq:MRNA).
The vaccine from British pharmaceutical company Astrazeneca plc (LON:AZN) has also been approved, but most domestically produced supplies have not been used in Japan and instead donated overseas.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses